Evidence map›Paper›PMID 31386018›Full record

ArticleNeuro-oncology practice2018

Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Ruichong Ma, Aswin Chari, Paul M Brennan, Andrew Alalade, Ian Anderson, Anna Solth, Hani J Marcus, Colin Watts, British Neurosurgical Trainee Research Collaborative

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Primary Intracranial High Grade Congenital Glial Lesions (PIHGCL): A systematic review of case reports from 1985 to 2025.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Ruichong MaDepartment of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford, UK.
Aswin ChariDivision of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Paul M BrennanDepartment of Neurosurgery, Centre for Clinical Brain Sciences, Western General Hospital, Edinburgh.
Andrew AlaladeDepartment of Neurosurgery, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Ian AndersonDepartment of Neurosurgery, Leeds General Infirmary, Leeds, UK.
Anna SolthDepartment of Neurosurgery, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Hani J MarcusDepartment of Neurosurgery, Charing Cross Hospital, London, UK.
Colin WattsDepartment of Neurosurgery, Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
British Neurosurgical Trainee Research Collaborative
Western General Hospital · GBCambridge University Hospitals NHS Foundation Trust · GBCharing Cross Hospital · GBImperial College London · GBJohn Radcliffe Hospital · GBLeeds General Infirmary · GBNational Hospital for Neurology and Neurosurgery · GBRoyal Victoria Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease.

methodsThe study was in 2 parts: an electronic questionnaire sent to United Kingdom neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective, multicenter observational study of current neurosurgical oncology practice.

resultsTwenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data were collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. Residual enhancing disease was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for residual enhancing disease. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit.

conclusionThere is a subset of patients for whom GTR is thought possible, but not achieved at surgery. For these patients, early repeat resection may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of GTR for residual enhancing disease and examine the potential benefit of this early re-intervention.

Indexed as

glioblastomaglioma surgeryneurooncologyresidual enhancing diseasesurvival

Identifiers

PMID31386018
PMCPMC6655490
OpenAlexW2766213096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.